Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174602 | 0.89 | KDM4E (0.48) | KDM4E | |
| SCHEMBL27911750 | 0.87 | KDM4E (0.47) | KDM4E | |
| SCHEMBL2173293 | 0.87 | PDE3B (0.50) | PDE3BPDE3AKDM4ECPB1CPB2 | |
| SCHEMBL4977770 | 0.77 | NOTUM (0.48) | PDE3BPDE3AKDM4ECPB1CPB2 | |
| SCHEMBL30582312 | 0.75 | MAP4K4 (0.43) | KDM4E | |
| SCHEMBL14701713 | 0.75 | PTGS2 (0.42) | KDM4E | |
| SCHEMBL4433834 | 0.74 | CPB2 (0.50) | PDE3BPDE3AKDM4ECPB1CPB2 | |
| SCHEMBL69486 | 0.74 | KDM4E (0.55) | KDM4ECPB1CPB2P4HTM | |
| SCHEMBL4425081 | 0.73 | MAP4K4 (0.51) | KDM4E | |
| SCHEMBL4424566 | 0.73 | NPC1 (0.53) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | PDE3B 2567/4885PDE3A 3152/4885KDM4E 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.